New drug hope for rare childhood immune disorders
Disease control
Recruiting now
This early-stage trial tests a new medicine called IMSB301 in people with rare diseases where the immune system attacks the body. The study includes up to 6 participants aged 12 and older. The main goal is to check if the drug is safe and how it behaves in the body.
Phase: PHASE1 • Sponsor: ImmuneSensor Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC